

Nice & Green resumes the financing agreement with Marinomed

Nyon Switzerland, 17 October 2023 – Nice & Green, the Swiss investment firm, is pleased to announce an adjustment to the convertible notes funding program with Marinomed Biotech AG (VSE:MARI), the Austrian science-based biotech company with globally marketed therapeutics. The adjustment involves a reduction of funding tranches from EUR 300,000 to EUR 160,000 as part of the original EUR 5.4 million financing agreement. This adjustment is aimed at considering share price, share liquidity, and the dilution effect on existing shareholders, all while securing ongoing project financing. The funding provided will not only enable Marinomed to secure project financing but also ensure financial flexibility as the company progresses towards operational profitability.

The investment agreement between Nice & Green and Marinomed is structured through a flexible Convertible Notes Funding Program, offering tranches of up to EUR 160,000. The contractual period extends for 12 months, lasting until October 2024. Marinomed has the option to suspend the issuance of individual tranches based on the company's actual cash needs and the prevailing conditions in the capital markets."

Bertrand Schmitt, Managing Partner of Nice & Green expressed: "Since 2021, we have been proud to support Marinomed, building a strong and enduring partnership. Today, we are excited to announce a new financing agreement with them. Our commitment to this operation reflects our confidence in their future great potential."

Pascal Schmidt, CFO of Marinomed, comments: "I am pleased that the cooperation with Nice & Green remains constructive and flexible. The extension and amendment of our Convertible Notes Funding Program is an already announced step that gives us the flexibility to successfully implement the out-licensing program for our product candidates even in the current environment. Although it is our highest priority, we cannot guarantee that we will conclude a contract in the current financial year. The bond provides us with the necessary security to continue pursuing our corporate strategy with a focus on partnering our innovative therapies."

About Nice & Green

Nice & Green is a leading privately held Swiss funding firm, active in the European market providing smart funding solutions to listed Micro-, Small- and Mid-Cap companies supporting their growth as partners. Find out more at [nicengreen.ch](https://www.nicengreen.ch).



About Marinomed Biotech AG

Marinomed Biotech AG (VSE:MARI) is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders.

The virology segment includes Carragelose®-based over the counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange. Find out more at marinomed.com.

Contact Information

Morgane Henchoz
MarCom Specialist

+41 22 361 36 97
mhenchoz@nicengreen.ch

Disclaimer

This press release is provided for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities or financial instruments, nor does it constitute investment advice or endorsement of any specific investment opportunity. The information contained in this press release is based on publicly available information and sources believed to be reliable, but no representation or warranty, express or implied, is made as to their accuracy, completeness, or correctness. This press release may contain forward-looking statements, including statements regarding future financial performance, business prospects, and growth strategies. These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied in such statements. The company and its affiliates do not accept any responsibility for any investment decisions made by individuals or entities based on the information provided in this press release. This press release is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The company reserves the right to amend or update this disclaimer at any time without notice.